Bioinformatics evaluation of targetom has-miR-622 and has-miR-92b-3p signaling pathways with regard to the function of PTEN in patients with non-small cell lung cancer

Important advancements in the treatment of non-small cell lung cancer (NSCLC) have been achieved over the past two decades, increasing our understanding of the disease biology and mechanisms of tumor progression, and advancing early detection and multimodal care. Over the last decade, the treatment of patients with advanced non-small cell lung cancer (NSCLC) has become reliant on tissue and/or blood biomarkers to help guide treatment decisions. There arenow multiple biomarker-defined patient subgroups, with evidence showing that treatment with targeted therapies has superior clinical outcomes when compared with traditional cytotoxic chemotherapy. MicroRNAs (miRNAs) are a class of small noncoding RNAs, which function in posttranscriptionalregulation of gene expression. They are powerful regulators of various cellular activities including cell growth, differentiation, development, and apoptosis. They have been linked to many diseases, and currently miRNA-mediated clinical trial has shown promising results for treatment of cancer and viral infection. In accordance with bioinformatics analysis and further studies of the Cancer Genome Atlas site, two microRNAs (has-miR-622 and has-miR-92b-3p) wereselected to study NSCLC through searching various databases namely NCBI, mirbase, mirwalk, David database to evaluate the potential role of aforementioned biomarkers in this type of cancer. Eventually, we predicted that in patients with progressive NSCLC, the expression levels of has-miR-622and has-miR-92b-3p should alter in the way that they decrease expression of PTEN as a tumor suppressor gene in oncogenic PI3K/AKT/mTOR signaling pathway

Keywords:

non-small-cell lung cancer (NSCLC) , microRNA , bioinformatics